Puretech Health Share Discussion Threads

[edwardt] 08/5/2019 15:14

and through she goes. to be fair, did not know about the law suit, glad we won it!!

[lendmeafiver] 07/5/2019 19:15

Almost £2

[lendmeafiver] 02/5/2019 18:08

Agree.

Surely given recent progress an ipo or other transaction at Gelesis has to be on the cards, will have a huge impact on the Prtc share price I expect.

[edwardt] 02/5/2019 15:07

market makers are holding it back - £2 is elusive!

[lendmeafiver] 01/5/2019 15:26

The buying continues, leaving the £1s behind shortly

[edwardt] 01/5/2019 08:26

no thanks old boy,

[lendmeafiver] 29/4/2019 11:20

www.telegraph.co.uk/news/2019/04/28/slimming-pill-offers-hope-millions-battle-against-obesity/

[lendmeafiver] 26/4/2019 17:59

Don’t blame you Edward, I think this company will be multi billion market cap in the not too distant future.

[edwardt] 26/4/2019 15:26

someone wants them. they ain't having mine.

[lendmeafiver] 26/4/2019 09:17

Karuna IPO, newsflow just keeps on coming, share price looking very strong with some decent buying volume.

[2niffy] 25/4/2019 08:29

Not much interest in the figs themself at this stage of the companies development, still big losses.However, more concern has been expressed re tapping of shareholders for funds to keep pipeline topped up.Raised fund as float 4 years ago at 160p and again last year at 160p.Company now says enough runway capital till 2022.6 affiliates have products that could be generating revenues in next 12 to 18 months.The internal R&D division could look to raise capital through US equity market.US institutions value biotech, pharma companies more favourably that UK players. Given the limited liquidity in the shares they could re rate very quickly.Company has finally come of age. Plenty of news flow to come in not to distant future. Akili FDA approval would really light the fuse.

[rambutan2] 25/4/2019 03:44

Finals out yesterday:

[lendmeafiver] 17/4/2019 11:38

Further good news today, all seems to have ignited some real interest here at long last.

[lendmeafiver] 16/4/2019 23:07

I think you are right Edward, huge potential for such a safe product that the market needs.

[edwardt] 16/4/2019 22:55

2 months in front of analyst expectationsfor approval . think it will be a huge success too!

[lendmeafiver] 16/4/2019 20:31

Been looking forward to the approval of Gelesis100 and pleased to see it has created a bit of interest here. When I first invested here I took the view that Gelesis very much covered the downside with all the other puretech pipelines being almost for free in the share price, I very much believe that to be the case now in my opinion. Like the name Plenity also.

[rambutan2] 16/4/2019 03:36

The PLENITY related webcast is available and worth a listen. It certainly has a huge potential market to aim for ie in the tens of millions of folks just in the USA.

[rambutan2] 16/4/2019 02:19

Just reminding myself that:

PureTech's percentage ownership of Gelesis is approximately 20.5% on a diluted basis and approximately 19.2% on a fully-diluted basis.
Note that: PureTech also has the right to receive a 2% royalty on the sales of certain Gelesis products, including Gelesis100 (aka PLENITY).

[rambutan2] 15/4/2019 19:43

On the back of the Gelesis news:

Peel Hunt today (April 15) reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 344p (from 320p).

Shares closed today up 10% at 180-182p. So still way below the broker/s target. Hopefully next weds results announcement will gain us a proper booster.

And as an aside, it's worth noting that if PRTC starts to approach that broker target it will qualify for the ftse 250.

[rambutan2] 15/4/2019 14:15

Happy days!

PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliate, Gelesis, has received marketing clearance from the United States Food and Drug Administration (FDA) for its first product, PLENITY(TM) (Gelesis100), a new and differentiated aid in weight management in adults with a Body Mass Index (BMI) of 25-40 kg/m(2) , when used in conjunction with diet and exercise. Nearly 150 million adults in the United States fall into this wide BMI range. PLENITY is the only prescription weight management product to be cleared for use by overweight adults with a BMI as low as 25 kg/m(2) , with or without comorbidities such as hypertension, type 2 diabetes or dyslipidaemia.

PLENITY is an orally administered capsule containing a non-stimulant, non-systemic, superabsorbent hydrogel. It is designed to absorb water and increase the volume and elasticity of the stomach and small intestine contents to help people feel full. Gelesis plans to initiate a targeted U.S. launch of PLENITY in the second half of 2019 and anticipates PLENITY will be broadly available by prescription in the U.S. in 2020.

Eric Elenko, PhD, co-founder and chief innovation officer at PureTech Health, said: "This FDA clearance of PLENITY(TM) marks a major accomplishment for PureTech Health and Gelesis. We congratulate the Gelesis team for bringing a truly novel approach for weight management to a vast population of people who have had limited or no prescription treatment options until now. The experienced commercial team at Gelesis is well-positioned to launch this exciting new therapy along with a deep base of investors who will help to support the launch.

"In-line with PureTech's overarching scientific focus and leadership in the BIG axis, Gelesis is developing its novel hydrogel platform technology for other chronic diseases such as non-alcoholic steatohepatitis and inflammatory bowel disease through its proprietary approach focused on modulating the gastrointestinal pathway.

"Committed to developing innovative medicines to address some of the largest health issues facing society today, PureTech Health has developed seven novel platforms from concept to clinical validation across our affiliate pipeline. FDA clearance of PLENITY is a landmark moment, providing strong validation of PureTech's ability to identify and develop an emerging area of biology into a new category of medicine for diseases with significant patient need. We look forward to building on this significant milestone with the many upcoming catalysts across our internal and affiliate pipelines."

[lendmeafiver] 11/4/2019 14:01

Another good one, plenty of newsflow to come also.

[edwardt] 11/4/2019 11:44

Gelesis- no more fatty liver- loving the use of the word 'compelling' in that rns

[lendmeafiver] 27/3/2019 14:16

It is another great RNS and all for a Market Cap of £465m!

[edwardt] 27/3/2019 12:45

gelesis - another great rns - 6 times the chance of losing more than 10% of your body weight - think how many americans could do with that product! if that was not enough - the mice study is mega interesting in its own right in that the product acts as a barrier for reduced toxicity into the gut - ergo it could help with controlling ibs - which i suffer from having seemingly inherited it from my mum!